They differ, for instance, in the oncogenic driver mutations, mainly alterations in MAPK signaling in cutaneous melanoma and alterations in GNAQ/GNA11 signaling or the BRCA1-associated protein BAP1 in uveal melanomas (Harbour et al., 2010; Phelps et al., 2022; Van Raamsdonk et al., 2009). The gene discussed is GNAQ; the disease is cutaneous melanoma.